Community-onset Bacterial Meningitis
An Antimicrobial Stewardship clinical summary.
These materials are intended for general clinical education and guidance. They are not a substitute for a clinician’s knowledge, skill or judgment in treating patients.
Note: Urgent Infectious Disease consultation strongly advised.
Background
Meningitis is inflammation of the meninges and is a medical emergency.
Initial assessment
- Empiric antibiotic therapy should begin as soon as possible in suspected cases; time to antibiotics should not exceed one hour.
- When feasible, perform a lumbar puncture and send for cell count, glucose, protein, culture and BioFire EM multiplex PCR.
- A head CT before lumbar puncture (LP) is recommended if any of the following are present:
- focal neurologic deficits
- new-onset seizures
- severely altered mental status (Glasgow Coma Scale score < 10)
- A severely immunocompromised state
- In patients without these findings, head CT before LP is not recommended and is associated with poorer outcomes.
- If LP is delayed (for example, for a head CT), start empiric therapy immediately after obtaining blood cultures, even if the diagnosis has not been confirmed.
Common pathogens
- S. pneumoniae
- N. meningitidis
- L. monocytogenes
- H. influenzae
Empiric therapy (first-line)
No known allergies:
- Ceftriaxone 2 g IV q12h
AND
- Vancomycin 25 mg/kg IV (loading dose once), then 15 mg/kg IV q12h
AND
- Dexamethasone 10 mg IV q6h for four days* (start immediately before, with, or up to four hours after the first antibiotic dose)
Consider also:
- Ampicillin 2 g IV q6h (if age ≥ 50, pregnant or immunocompromised)
- Acyclovir 10 mg/kg IV q8h if clinical features of encephalitis are present
Alternative regimens for allergy to first-line regimen
Penicillin or amoxicillin allergy (unknown reaction, intolerance and/or type 1 hypersensitivity):
- Ceftriaxone 2 g IV q12h
AND
- Vancomycin 25 mg/kg IV (loading dose once), then 15 mg/kg IV q12h
AND
- Dexamethasone 10 mg IV q6h for four days* (start immediately before, with or up to four hours after the first dose of antibiotics)
Consider also:
- TMP-SMX 5 mg/kg (based on TMP component) IV q6h in place of ampicillin (if age ≥ 50, pregnant or immunocompromised)
- Acyclovir 10 mg/kg IV q8h if clinical features of encephalitis are present
Severe systemic or cutaneous reaction (unable to use any beta-lactem):
- Moxifloxacin 400 mg IV q24h (in place of ceftriaxone)
AND
- Vancomycin 25 mg/kg IV (loading dose once), then 15 mg/kg IV q12h
AND
- Dexamethasone 10 mg IV q6h for four days* (start immediately before, with or up to four hours after the first dose of antibiotics)
Consider also:
- TMP-SMX 5 mg/kg (based on TMP component) IV q6h in place of ampicillin (if age ≥ 50, pregnant or immunocompromised)
- Acyclovir 10 mg/kg IV q8h if clinical features of encephalitis are present
Targeted therapy for common pathogens
| Organism | Antibiotic susceptibility | Targeted therapy | Duration |
|---|---|---|---|
| S. pneumoniae | Penicillin-susceptible | Penicillin G 4 million units IV q4h | 10 days |
| Penicillin-resistant AND ceftriaxone-susceptible | Ceftriaxone 2 g IV q12h | ||
| Penicillin-resistant AND ceftriaxone-resistant | Vancomycin 15 mg/kg IV q8–12h** plus ceftriaxone 2 g IV q12h | ||
| H. influenzae | Ampicillin-susceptible | Ampicillin 2 g IV q4h | 7 days |
| Ampicillin-resistant | Ceftriaxone 2 g IV q12h | ||
| N. meningitidis | Penicillin-susceptible | Penicillin G 4 million units IV q4h | 7 days |
| Penicillin-resistant | Ceftriaxone 2 g IV q12h | ||
| L. monocytogenes | n/a | Ampicillin 2 g IV q4h plus gentamicin 1.7 mg/kg IV q8h | ≥ 21 days |
| **To achieve trough level of 15–20 mg/L | |||
Clinical pearls
Adjunctive dexamethasone:
- Associated with decreased mortality and neurologic sequelae in S. pneumoniae and H. influenzae → continue dexamethasone for four days
- Shows no proven benefit in N. meningitidis and increased mortality in L. monocytogenes → discontinue upon microbiological diagnosis
Infection control:
- Chemoprophylaxis for close contacts and droplet isolation for the first 24 hours of therapy are indicated only for N. meningitidis and H. influenzae
Accordion Items
References
- Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284.
- van de Beek D, Cabellos C, Dzupova O, et al.; ESCMID Study Group for Infections of the Brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62.
- van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. Clin Microbiol Infect. 2017;23(9):601-606.
- Alford MA, Karlowsky JA, Adam HJ, et al. Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2020. J Antimicrob Chemother. 2023 May 3;78(Suppl 1):i8-i16.
- de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549-1556.
- van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol. 2010;9(3):254-263.